News

News


22 Nov 2015
20 November 2015 – Geneva, Switzerland — The world is losing its battle with tuberculosis (TB), which is now the biggest infectious killer globally, causing 1.5 million deaths every year. Without a clear investment plan and a complete overhaul in how this disease is tackled, TB is unlikely to be...
22 Nov 2015
Cape Town, South Africa, Dec. 5, 17:30 – 20:30 We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2015 at Southern Sun Cape Sun Hotel , Cape Town, South Africa, on Saturday, Dec. 5th from 17:30 to 20:30. This meeting is held before the 46th Union World...
11 Jun 2015
10 June 2015 – Geneva, Switzerland – The Stop TB Partnership is today launching the online consultation into the first public draft of the Global Plan to Stop TB 2016-2020. The consultation process is open to everyone to share information, ideas and experiences, and, will run from 10 June to 10...
31 May 2015
Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis Volume 211 suppl 3 June 15, 2015 Click here for access to supplement Articles: Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen...
19 Feb 2015
TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes...
7 Jan 2015
Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...
23 Oct 2014
22 OCTOBER 2014 AT 12:01 a.m. EDT CONTACT Mike Frick, Treatment Action Group +1 405.388.4490 New York, NEW YORK, OCTOBER 22, 2014 —Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in...
21 Sep 2014
We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum , Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00. This meeting is held before the 45th Union World Conference on Lung Health (The Union). During the...
8 Sep 2014
Moxifloxacin Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with...
20 Jul 2014
Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...
14 Jul 2014
A new study published by Dr. Kyu Rhee ’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics. Physicians and scientists have known for many years that tuberculosis is intrinsically resistant to...
10 Jun 2014
On June 9 th , the Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease. The policy reports were the culmination of major findings...
1 Jun 2014
The Kick TB Campaign is a unique project that uses football (soccer), the World’s most popular sport, to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of...
27 May 2014
Dr. Iwao Ojima Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. His group recently published a paper in PLOS One entitled A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against...
29 Apr 2014
The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis. The press release from Otsuka can be found here Related...

Pages